Gelteq (GELS) Competitors $1.92 0.00 (0.00%) As of 02/21/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsTrends GELS vs. CLSD, IMAB, PYRGF, EPIX, ASRT, KPTI, PMVP, INCR, ME, and MURAShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Clearside Biomedical (CLSD), I-Mab (IMAB), PyroGenesis Canada (PYRGF), ESSA Pharma (EPIX), Assertio (ASRT), Karyopharm Therapeutics (KPTI), PMV Pharmaceuticals (PMVP), InterCure (INCR), 23andMe (ME), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical products" industry. Gelteq vs. Clearside Biomedical I-Mab PyroGenesis Canada ESSA Pharma Assertio Karyopharm Therapeutics PMV Pharmaceuticals InterCure 23andMe Mural Oncology Gelteq (NASDAQ:GELS) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, community ranking, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations. Do insiders and institutionals hold more shares of GELS or CLSD? 18.8% of Clearside Biomedical shares are held by institutional investors. 9.2% of Clearside Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is GELS or CLSD more profitable? Gelteq has a net margin of 0.00% compared to Clearside Biomedical's net margin of -413.83%. Company Net Margins Return on Equity Return on Assets GelteqN/A N/A N/A Clearside Biomedical -413.83%N/A -92.90% Which has preferable valuation and earnings, GELS or CLSD? Gelteq has higher earnings, but lower revenue than Clearside Biomedical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGelteqN/AN/AN/AN/AN/AClearside Biomedical$8.23M8.75-$32.49M-$0.45-2.11 Does the media prefer GELS or CLSD? In the previous week, Clearside Biomedical had 3 more articles in the media than Gelteq. MarketBeat recorded 3 mentions for Clearside Biomedical and 0 mentions for Gelteq. Clearside Biomedical's average media sentiment score of 0.82 beat Gelteq's score of 0.00 indicating that Clearside Biomedical is being referred to more favorably in the news media. Company Overall Sentiment Gelteq Neutral Clearside Biomedical Positive Do analysts rate GELS or CLSD? Clearside Biomedical has a consensus target price of $5.33, indicating a potential upside of 461.40%. Given Clearside Biomedical's stronger consensus rating and higher possible upside, analysts plainly believe Clearside Biomedical is more favorable than Gelteq.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Clearside Biomedical 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in GELS or CLSD? Clearside Biomedical received 368 more outperform votes than Gelteq when rated by MarketBeat users. CompanyUnderperformOutperformGelteqN/AN/AClearside BiomedicalOutperform Votes36867.28% Underperform Votes17932.72% SummaryClearside Biomedical beats Gelteq on 9 of the 11 factors compared between the two stocks. Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.12M$7.06B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.7326.0419.11Price / SalesN/A306.03447.4676.36Price / CashN/A65.6738.0134.83Price / BookN/A6.717.644.62Net IncomeN/A$138.33M$3.18B$245.85M7 Day Performance-9.00%-2.63%-2.00%-2.61%1 Month Performance-27.55%-2.33%-0.44%-2.14%1 Year PerformanceN/A-5.33%16.44%12.98% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$1.92flatN/AN/A$18.12MN/A0.00N/AGap UpCLSDClearside Biomedical2.0839 of 5 stars$1.05+1.0%$5.33+407.9%-26.9%$79.63M$8.23M-2.3330IMABI-Mab3.3966 of 5 stars$0.97-0.9%$8.00+724.7%-38.9%$79.06M$3.89M0.00380News CoveragePYRGFPyroGenesis CanadaN/A$0.43-1.6%N/A+21.0%$78.90M$9.14M-7.1490Gap DownHigh Trading VolumeEPIXESSA Pharma3.1186 of 5 stars$1.73flat$9.50+449.1%-79.0%$76.80MN/A-2.5150ASRTAssertio2.9964 of 5 stars$0.80-1.1%$3.25+304.7%+3.0%$76.67M$152.07M-1.1020Short Interest ↓Positive NewsKPTIKaryopharm Therapeutics3.7783 of 5 stars$0.60-4.8%$5.00+733.3%-50.5%$75.71M$146.03M-0.53380Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumePMVPPMV Pharmaceuticals2.561 of 5 stars$1.44+5.1%$5.50+281.9%-16.6%$74.52MN/A-1.4450High Trading VolumeINCRInterCure0.3591 of 5 stars$1.61-0.7%N/A-15.0%$73.32M$96.61M0.00350News CoverageME23andMe1.3608 of 5 stars$2.72-2.9%$9.40+245.6%-81.9%$72.98M$219.64M-0.18770Analyst ForecastNews CoverageMURAMural Oncology3.5982 of 5 stars$4.27-0.9%$16.00+274.7%-13.6%$72.68MN/A-0.47119 Related Companies and Tools Related Companies Clearside Biomedical Competitors I-Mab Competitors PyroGenesis Canada Competitors ESSA Pharma Competitors Assertio Competitors Karyopharm Therapeutics Competitors PMV Pharmaceuticals Competitors InterCure Competitors 23andMe Competitors Mural Oncology Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GELS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
